|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Patients completed a set of questionnaires on working status and educational level, physical functioning (Frenchay Activities Index, FAI), mental functioning (Hospital Anxiety and Depression Scale, HADS), Coping Orientations to Problems Experienced, (COPE easy) and quality of life (Short-Form(SF)-36 and EQ(Euroqol)-5D).
|
27402347 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
We report the validation process of a 4-factor structure of the French version of the Brief COPE in a French sample of individuals facing a singular life event, such as cancer, including patients and their caregivers.
|
28077139 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Study participants from a comprehensive cancer center were asked to complete a series of instruments that measured their perception of the patient's cognitive dysfunction (revised memory and behavior problems checklist, RMBC), their own personal resilience (Resilience Scale, RS), and their utilization of a broad range of coping responses (COPE inventory and Emotional-Approach Coping scale).
|
27921222 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis.
|
28574777 |
2017 |
|
Anxiety
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The main measurements were anxiety (Hamilton scale), coping (Brief COPE), subjective burden (Caregiver Strain Index), objective burden and sex of the caregiver.
|
31083624 |
2019 |
|
Anxiety Disorders
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The main measurements were anxiety (Hamilton scale), coping (Brief COPE), subjective burden (Caregiver Strain Index), objective burden and sex of the caregiver.
|
31083624 |
2019 |
|
Substance Use Disorders
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Military veterans (N = 81, 90.1% male) with current SUD and PTSD were randomized to 12 sessions of COPE or Relapse Prevention (RP).
|
30529244 |
2019 |
|
Substance Use Disorders
|
0.040 |
GeneticVariation
|
group |
BEFREE |
To address this gap in the literature, we utilized data from a larger study investigating a 12-week integrated, exposure-based treatment (i.e., Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure, or COPE) to examine treatment outcomes by single vs. poly-SUD status.
|
31009834 |
2019 |
|
Depressive Symptoms
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
<b>Objectives:</b> To examine (1) correlates of religious coping, and (2) associations of religious coping at baseline with evaluation of treatment acceptability and depressive symptom severity outcomes of short-term psychotherapeutic depression treatments among 277 low-income homebound older adults (70% female; 41% non-Hispanic White, 30% African American, and 29% Hispanic) who participated in a treatment effectiveness trial.<b>Method:</b> Religious coping was measured with a 2-item subscale of the Brief COPE.
|
31791141 |
2019 |
|
Depressive Symptoms
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Questionnaires addressed patients' experience with cancer and included measures of coping (COPE and Emotional Approach Coping), social support (Interpersonal Support Evaluation List), and depressive symptoms (Center for Epidemiologic Studies Depression Scale).
|
29265835 |
2018 |
|
Depressive Symptoms
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), and coping (Brief COPE) at baseline and 24 weeks.
|
29140772 |
2018 |
|
Anxiety
|
0.040 |
Biomarker
|
disease |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Anxiety
|
0.040 |
Biomarker
|
disease |
BEFREE |
Patients completed a set of questionnaires on working status and educational level, physical functioning (Frenchay Activities Index, FAI), mental functioning (Hospital Anxiety and Depression Scale, HADS), Coping Orientations to Problems Experienced, (COPE easy) and quality of life (Short-Form(SF)-36 and EQ(Euroqol)-5D).
|
27402347 |
2017 |
|
Anxiety Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
Patients completed a set of questionnaires on working status and educational level, physical functioning (Frenchay Activities Index, FAI), mental functioning (Hospital Anxiety and Depression Scale, HADS), Coping Orientations to Problems Experienced, (COPE easy) and quality of life (Short-Form(SF)-36 and EQ(Euroqol)-5D).
|
27402347 |
2017 |
|
Anxiety Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Substance Use Disorders
|
0.040 |
GeneticVariation
|
group |
BEFREE |
A growing literature provides evidence for the use of integrated treatments (e.g., Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; COPE); however, no known studies have applied COPE via telehealth.
|
28118514 |
2017 |
|
Substance Use Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
A recent adaptation of PE, called Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure [COPE], integrates substance use disorder treatment with PE in the same timeframe (twelve 90-minute sessions, 8 of which include imaginal exposure).
|
28329434 |
2017 |
|
Depressive Symptoms
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Results revealed significantly lower depressive symptoms at post-treatment in the COPE group, as compared to the relapse prevention group.
|
28098747 |
2017 |
|
Anxiety
|
0.040 |
Biomarker
|
disease |
BEFREE |
Brief COPE scores showed that self-blame, behavioral disengagement, self-distraction, use of emotional support, venting, denial, and less acceptance were related to increased anxiety.
|
26007689 |
2015 |
|
Anxiety Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
Brief COPE scores showed that self-blame, behavioral disengagement, self-distraction, use of emotional support, venting, denial, and less acceptance were related to increased anxiety.
|
26007689 |
2015 |
|
Mixed anxiety and depressive disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
To assess the feasibility, acceptability, and preliminary effects of a cognitive-behavioral intervention (Creating Opportunities for Patient Empowerment [COPE]) on depression, anxiety, and quality of life (QOL) in a sample of adolescent refugees (13-17 years) living in Lebanon.
|
30477312 |
2018 |
|
Mixed anxiety and depressive disorder
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Psychological distress, including depression, anxiety, stress, and overall distress (DASS-21); use of different coping styles (Brief COPE); and perceptions of HSCT and coping appraisals (Brief IPQ)..
|
27991602 |
2017 |
|
Mixed anxiety and depressive disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Measures included IBS severity (Irritable Bowel Syndrome Severity Scoring System), coping patterns (Carver Brief COPE), visceral sensitivity (Visceral Sensitivity Index), illness perceptions (Brief Illness Perceptions Questionnaire), psychological distress (Depression, Anxiety and Stress Scale), and quality of life (IBS Quality of Life scale; IBS-QoL).
|
27045996 |
2017 |
|
Alcohol Use Disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
<i>Methods:</i> Through a cross-sectional and multicenter study, 122 AUD people (74 men and 48 women) responded to a sociodemographic interview and three self-questionnaires assessing personality (BFI), coping strategies (brief COPE), and anxiety-depression symptomatology (HADS).
|
30973041 |
2019 |